Dash Acquisitions Inc. Boosts Holdings in Eli Lilly and Company $LLY

Dash Acquisitions Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 2.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 485 shares of the company’s stock after buying an additional 13 shares during the quarter. Dash Acquisitions Inc.’s holdings in Eli Lilly and Company were worth $387,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Morris Financial Concepts Inc. grew its holdings in Eli Lilly and Company by 2.0% in the 2nd quarter. Morris Financial Concepts Inc. now owns 2,238 shares of the company’s stock valued at $1,745,000 after buying an additional 43 shares during the period. Rosenberg Matthew Hamilton grew its holdings in shares of Eli Lilly and Company by 3.7% during the 2nd quarter. Rosenberg Matthew Hamilton now owns 666 shares of the company’s stock worth $519,000 after purchasing an additional 24 shares during the period. Mutual Advisors LLC grew its holdings in shares of Eli Lilly and Company by 0.5% during the 2nd quarter. Mutual Advisors LLC now owns 63,791 shares of the company’s stock worth $51,842,000 after purchasing an additional 328 shares during the period. Essex LLC grew its holdings in shares of Eli Lilly and Company by 12.8% during the 2nd quarter. Essex LLC now owns 2,486 shares of the company’s stock worth $1,938,000 after purchasing an additional 282 shares during the period. Finally, Ritholtz Wealth Management grew its holdings in shares of Eli Lilly and Company by 5.1% during the 2nd quarter. Ritholtz Wealth Management now owns 22,139 shares of the company’s stock worth $17,258,000 after purchasing an additional 1,065 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.7%

NYSE LLY opened at $826.20 on Thursday. The stock has a market cap of $781.97 billion, a PE ratio of 54.00, a P/E/G ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $935.63. The business has a 50 day moving average price of $745.96 and a two-hundred day moving average price of $766.28. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company posted $3.92 EPS. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. UBS Group decreased their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $948.06.

Insider Buying and Selling

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.